Contact
Please use this form to send email to PR contact of this press release:
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
TO:
Please use this form to send email to PR contact of this press release:
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
TO: